NASDAQ · Financial Statements
Allogene Therapeutics, Inc. (ALLO) Financial Statements
$1.31
NASDAQ: ALLO
Market Cap $452.59M
Overview Financials Dividend
Allogene Therapeutics, Inc. most recently reported annual revenue of $0, a net loss of $191.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025
Revenue $114.0M $0 $0 $0 $0 Operating Profit $-180.0M $-336.0M $-328.0M $-273.0M $-207.0M Net Profit $-182.0M $-340.0M $-327.0M $-258.0M $-191.0M EPS $-1.34 $-2.38 $-2.09 $-1.32 $-0.87 Op Margin -157.9% -215087.2% -344986.3% -1241813.6% —
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025
Total Assets $1.1B $822.0M $643.0M $549.0M $416.0M Total Liabilities $126.0M $155.0M $131.0M $127.0M $123.0M Cash $173.0M $62.0M $83.0M $75.0M $52.0M Borrowings $73.0M $101.0M $95.0M $91.0M $83.0M
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025
Operating Cash Flow $-185.0M $-221.0M $-238.0M $-200.0M $-149.0M Investing Cash Flow $142.0M $101.0M $162.0M $75.0M $95.0M Financing Cash Flow $0 $0 $5.0M $2.0M $7.0M Net Cash Flow $-9.0M $-111.0M $21.0M $-8.0M $-24.0M Free Cash Flow $-206.0M $-226.0M $-239.0M $-201.0M $-150.0M
Valuation & Return Ratios
Metric Value PEG Ratio -0.04 EV / EBITDA -3.60 FCF Yield -19.82% Quick Ratio 10.72 Interest Coverage -138.71 Return 1Y 9.64% Return 3Y -63.16% Return 5Y -91.72%
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer .